Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | GSK3A | P49840 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30815301 | 1.00 | MEN1 (0.51) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226363 | 0.83 | MEN1 (0.56) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226844 | 0.83 | MEN1 (0.53) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL21671950 | 0.83 | MAPT (0.58) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226888 | 0.83 | MEN1 (0.53) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226492 | 0.82 | HSF1 (0.55) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226653 | 0.81 | MEN1 (0.51) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226136 | 0.81 | MEN1 (0.51) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL27226540 | 0.81 | MEN1 (0.51) | MEN1KMT2AMAPTMAPK1POLB | |
| SCHEMBL30815539 | 0.81 | MAPT (0.41) | MEN1KMT2AMAPTMAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MEN1 1284/4885KMT2A 1301/4885MAPT 1885/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MEN1 1284/4885KMT2A 1301/4885MAPT 1885/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | MEN1 1284/4885KMT2A 1301/4885MAPT 1885/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | MEN1 1284/4885KMT2A 1301/4885MAPT 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.